188 related articles for article (PubMed ID: 19795913)
21. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
22. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
23. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
24. Twelve immunotherapy drugs that could cure cancers.
Cheever MA
Immunol Rev; 2008 Apr; 222():357-68. PubMed ID: 18364014
[TBL] [Abstract][Full Text] [Related]
25. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
26. Tumor specific CD8+ T cells in patients with lung cancer and healthy individuals.
Karanikas V; Germenis A
J BUON; 2009 Sep; 14 Suppl 1():S153-7. PubMed ID: 19785058
[TBL] [Abstract][Full Text] [Related]
27. Considerations on clinical use of T cell immunotherapy for cancer.
Plautz GE; Cohen PA; Shu S
Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
[TBL] [Abstract][Full Text] [Related]
28. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
[TBL] [Abstract][Full Text] [Related]
29. Poxviruses as vectors for cancer immunotherapy.
Kwak H; Hörig H; Kaufman HL
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450
[TBL] [Abstract][Full Text] [Related]
30. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
31. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunogene therapy.
Yoshizawa H; Kagamu H; Gejyo F
Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
[TBL] [Abstract][Full Text] [Related]
33. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
[TBL] [Abstract][Full Text] [Related]
34. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
Speiser DE; Romero P
Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
[TBL] [Abstract][Full Text] [Related]
35. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
36. Peptide-based immunotherapy for multiple myeloma: current approaches.
Zhou FL; Meng S; Zhang WG; Wei YC; Cao XM; Bai GG; Wang BY
Vaccine; 2010 Aug; 28(37):5939-46. PubMed ID: 20619381
[TBL] [Abstract][Full Text] [Related]
37. Development of optimized cryptic peptides for immunotherapy.
Menez-Jamet J; Kosmatopoulos K
IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cells in cancer immunotherapy.
Schuler G
Eur J Immunol; 2010 Aug; 40(8):2123-30. PubMed ID: 20853498
[TBL] [Abstract][Full Text] [Related]
39. Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors.
Wang GZ; Tang XD; Lü MH; Gao JH; Liang GP; Li N; Li CZ; Wu YY; Chen L; Cao YL; Fang DC; Yang SM
Cancer Prev Res (Phila); 2011 Aug; 4(8):1285-95. PubMed ID: 21505182
[TBL] [Abstract][Full Text] [Related]
40. Cancer vaccine development: on the way to break immune tolerance to malignant cells.
Mocellin S; Rossi CR; Nitti D
Exp Cell Res; 2004 Oct; 299(2):267-78. PubMed ID: 15350526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]